Pharmacyclics

Pharmacyclics LLC is an American biopharmaceutical company based in Sunnyvale, California, focused on the development of cancer therapies. Its primary product is ibrutinib (Imbruvica), a Bruton's tyrosine kinase (BTK) inhibitor. Pharmacyclics was acquired by AbbVie in 2015.

Source: https://www.abbvie.com/

ibrutinibImbruvica

BTK inhibitor

Imbruvica (ibrutinib) is the first-in-class Bruton tyrosine kinase inhibitor. Taken by mouth, it blocks the survival signalling of malignant B cells and transformed the treatment of chronic lymphocytic leukaemia, Waldenstrom macroglobulinaemia and mantle cell lymphoma.

B-cell cancers such as chronic lymphocytic leukaemia rely on signals passing through a protein called Bruton tyrosine kinase. Ibrutinib binds to BTK a

1 medicine explained